Video content above is prompted by the following questions:
- With RSV season shifting earlier in the year and hospitalization rates increasing, what is needed for payers to activate early coverage for RSV vaccines in adults?
- How has the recommendation from the ACIP (Advisory Committee on Immunization Practices) impacted coverage of an RSV vaccine?
- How has coverage by insurance companies been since the approval (60+) of the 2 RSV vaccines?
- How can potential insurance coverage for RSV vaccines for those between 50-59 be optimized?